- Home
- » Tags
- » Satralizumab
Top View
- Multiple Sclerosis
- (INN) for Biological and Biotechnological Substances
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
- COVID-19 in Patients with Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America from the Covims Registry
- Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
- Lumicera Specialty Drug List
- Enspryng™ (Satralizumab)
- NEW--Npf-MASTER LIST.Xlsx
- Division of Medical Services Table of Contents
- Self-Administered Specialty Drug List
- 093 Soliris, Ultomiris, and Uplizna Policy
- Roche Template
- Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-Analysis of Randomized Control Trials
- Development of Therapeutic Antibodies for the Treatment Of
- New Roche Data at the 2019 AAN Annual Meeting Showcase Breadth
- Satralizumab-Mwge (Enspryng™) New Drug Update
- 5.01.564 Pharmacotherapy of Miscellaneous Autoimmune Diseases
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders
- Specialty Pipeline MONTHLY UPDATE
- Transfer of Monoclonal Antibodies Into Breastmilk in Neurologic and Non-Neurologic Diseases
- Enspryng, INN-Satralizumab
- Study Protocol
- Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated Or Associated to Immune-Mediated Inflammatory Diseases
- A View Into Upcoming Specialty & Traditional Drugs
- 761149Orig1s000
- Mandatory Specialty Drug List
- Corporate Medical Policy Eculizumab (Soliris®) “Notification”
- Enspryng™ (Satralizumab)
- Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
- Satralizumab
- PDF of Antibody News
- Self-Administered Medications List
- Specialty Pipeline Monthly Update June 2021
- Willkie's Biologics and Biosimilars Newsletter
- CHANGES to the HIGHMARK DRUG FORMULARIES Following Is the Update to the Highmark Drug Formularies and Pharmaceutical Management Procedures for January 2021
- Enspryng™ (Satralizumab-Mwge) (Subcutaneous) Document Number: IC-0563 Last Review Date: 09/01/2020 Date of Origin: 09/01/2020 Dates Reviewed: 09/2020
- 2021 Medicaid Preapproval Criteria
- Abbvie Defends Humira with Aggressive Discount in EU
- Drugs Limited to Specific Pharmacies | Kaiser Permanente Washington
- Prior Authorization Criteria for Approval
- Investor Update
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder